Source: International Congress 2018 – Pulmonary fibrosis: from models to patients
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Simon (Brasília, Brazil), C. Melo-Silva (Brasília, Brazil), P. Veloso-Junior (Brasília, Brazil), V. Amado (Brasília, Brazil), F. Figueiredo (Brasília, Brazil), A. Bocca (Brasília, Brazil). A novel chronic murine model of idiopathic pulmonary fibrosis. 998

Member's Comments

No comment yet.

Related content which might interest you: In vitro modelling of epithelia-fibroblast interactions in idiopathic pulmonary fibrosis Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 A first step against idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 130-131 Year: 2011 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 The genetic basis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1717-1727 Year: 2015 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Immunological profiling of chronic obstructive airways disease and idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 Evaluating disease severity in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017 Year: 2017 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Towards a better diagnosis of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 108-113 Year: 2011 The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Combined idiopathic pulmonary fibrosis and emphysema: functional characterization Source: Eur Respir J 2004; 24: Suppl. 48, 283s Year: 2004 Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016 Year: 2017